BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31

BIOMARIN PHARMACEUTICAL INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$54.67−0.01 (-0.02%)

Close on Oct 19, 2026

Market cap: $10.63B
P/E (TTM): 143.9
Dividend yield: –

BIOMARIN PHARMACEUTICAL INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31
Revenue	3,221	2,854	2,419	2,096	1,846	1,860	1,704	1,491	1,314	1,117	890	749	548	501	441	376	325	296
Cost of Revenue	717	580	532	503	471	524	359	315	242	210	152	122	88	92	84	70	66	53
Gross Profit	2,504	2,274	1,887	1,593	1,376	1,336	1,345	1,176	1,072	907	738	627	460	409	357	306	259	244
Research & Development	922	747	747	650	629	628	715	696	611	662	635	462	355	302	214	147	115	93
Selling, General & Admin	1,153	1,009	892	823	759	738	681	604	554	477	402	302	235	198	175	152	124	107
Advertising Expenses	51	35	28	25	30	29	–	–	–	–	–	–	–	–	–	–	–	–
Total Costs & Expenses	2,812	2,370	2,233	1,935	1,929	1,904	1,805	1,615	1,328	1,920	1,001	842	704	611	475	376	308	257
Operating Income	409	484	186	161	-82	-43	-100	-124	-15	-803	-111	-93	-156	-110	-34	0.54	16	40
Interest Expense	11	13	17	16	15	29	23	44	43	39	38	37	10	7.64	8.41	11	14	16
Interest & Investment Income	75	75	58	18	10	17	23	23	15	7.49	4.50	5.94	3.08	2.58	2.93	4.11	5.09	16
Income from Equity Investments	–	–	–	–	–	-0.01	-0.59	-0.55	-1.29	-0.54	-0.82	-0.88	-1.15	-1.22	-2.43	-2.99	-2.59	-2.27
Asset Impairment Charges	125	20	39	0	0	0	0	0	0	599	212	0	0.94	–	–	–	–	–
Gain (Loss) on Investments	–	–	–	–	–	–	–	–	–	-0.10	–	–	–	0	0	0.90	1.59	0
Gain (Loss) on Sale of Assets	0	10	0	108	0	53	25	50	–	–	–	–	–	–	–	–	–	–
Pretax Income	482	542	189	150	-75	-49	-95	-143	-36	-831	-155	-125	-177	-118	-44	-21	0.57	33
Income Tax Expense	134	115	21	8.02	-11	-903	-71	-65	81	-201	17	9.10	-0.15	-3.93	10	-227	1.05	2.59
Net Income	349	427	168	142	-64	854	-24	-77	-117	-630	-172	-134	-176	-114	-54	206	-0.49	31
Net Income to Common	349	427	168	142	-64	854	-24	-77	-117	-630	-172	-134	–	-114	-54	206	-0.49	–
EPS (Basic)(per share)	1.82	2.25	0.89	0.76	-0.35	4.72	-0.13	-0.44	-0.67	-3.80	-1.07	-0.92	-1.28	-0.95	-0.48	2.00	0.00	0.31
EPS (Diluted)(per share)	1.80	2.21	0.87	0.75	-0.35	4.50	-0.13	-0.44	-0.67	-3.81	-1.07	-0.92	-1.28	-0.95	-0.48	1.73	0.00	0.29
Shares Outstanding (Basic, Weighted)(shares)	192	190	188	185	183	181	179	177	174	166	160	146	138	120	112	103	100	99
Shares Outstanding (Diluted, Weighted)(shares)	197	197	192	189	183	192	179	177	174	166	160	146	138	120	112	126	100	104
EBITDA	489	581	290	263	26	62	4.84	-28	73	-707	-64	-47	-120	-66	1.16	28	37	57

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 76.1%
Operating margin: 4.4%
Net margin: 2.1%
Return on equity, FY2025: 5.9%

Financial strength

Current ratio: 2.39
Debt to equity: 0.66
Debt to assets: 35.7%
Cash to current liabilities: 52.5%

Valuation

P/E ratio: 143.9
Price to sales: 3.12
Price to book: 1.68
Dividend yield: –